Curewell Capital Closes Oversubscribed Inaugural Fund at $535 Million

Audio By Carbonatix

LOS ANGELES--(BUSINESS WIRE)--Aug 20, 2025--

Curewell Capital (“Curewell”), a private equity firm focused on building industry-leading middle-market healthcare companies, announced the closing of Curewell Capital I, LP (together with its related vehicles, the “Fund”) at its hard cap of $535 million. The inaugural Fund was raised in a single closing and completed less than five months after launch.

Curewell secured commitments from a diverse group of global institutional investors, comprised of leading endowments, foundations, pensions, insurance companies, consultants, family offices, and industry executives.

Curewell is led by Michael Dal Bello and Ceron Rhee, who have worked together for nearly two decades, including their shared tenures at Blackstone and more recently at Pritzker Private Capital, where they led the healthcare investment practice. The Fund builds on the team’s established strategy of acquiring leading U.S. healthcare businesses across healthcare services, pharmaceutical services, medical devices, and healthcare technology. Curewell seeks to partner with experienced founders and management teams leading extraordinary healthcare companies to help accelerate growth and operational performance.

“We are grateful for the trust and support of an exceptional group of investors. We are further honored to work with founders, owners, and management teams who share our vision of increasing access to healthcare, lowering overall system costs, and enhancing quality of care. We look forward to building lasting value together,” said Michael Dal Bello, Co-Founder and Partner.

“This fund represents our next chapter in partnering with accomplished teams advancing innovation and transformation in healthcare,” added Ceron Rhee, Co-Founder and Partner. “We are seeing strong secular tailwinds across our key areas of focus, providing meaningful opportunities for companies to improve outcomes and drive efficiencies throughout the U.S. healthcare system.”

Probitas Partners acted as the exclusive placement advisor for the Fund, and Kirkland & Ellis LLP acted as fund counsel.

About Curewell Capital

Curewell is a Los Angeles–based private equity firm focused on building industry-leading middle-market healthcare companies headquartered in North America. Drawing upon decades of investment and operating experience across healthcare services, pharmaceutical services, medical devices, and healthcare technology, Curewell seeks to partner with founders and management teams leading premier companies that improve patient outcomes, create efficiencies, and foster innovation. Curewell’s proprietary GRO™ framework is tailored to each company to drive long-term value through growth and operational excellence. For additional information, please visit www.curewellcapital.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250820067361/en/

CONTACT: Curewell Capital

[email protected]

(310) 361-1510

KEYWORD: UNITED STATES NORTH AMERICA CANADA CALIFORNIA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL FINANCE GENERAL HEALTH HEALTH MEDICAL DEVICES HEALTH TECHNOLOGY PROFESSIONAL SERVICES

SOURCE: Curewell Capital

Copyright Business Wire 2025.

PUB: 08/20/2025 08:30 AM/DISC: 08/20/2025 08:30 AM

http://www.businesswire.com/news/home/20250820067361/en